An appraisal of FDA approvals for adult solid tumours in 2017–2021: has the eagle landed?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
https://www.nature.com/articles/s41571-022-00636-y.pdf
Reference56 articles.
1. Cancer Moonshot Task Force. Cancer Moonshot: Report of the Cancer Moonshot Task Force (The White House, 2016).
2. Cherny, N. I. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol. 26, 1547–1573 (2015).
3. Cherny, N. I. et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann. Oncol. 28, 2340–2366 (2017).
4. Cherny, N. I. et al. Comparative assessment of clinical benefit using the ESMO-Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score. J. Clin. Oncol. 37, 336–349 (2018).
5. Dafni, U. et al. Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. ESMO Open 2, e000216 (2017).
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Progress and Challenges of the New Conditional Approval Process in China: A Pooled Analysis From 2018 to 2021;Clinical Therapeutics;2023-11
2. Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting;JCO Global Oncology;2023-09
3. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma;JAMA Oncology;2023-08-03
4. Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?;Clinical Drug Investigation;2023-07-28
5. Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor Inhibitors;JAMA Network Open;2023-07-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3